Nature Medicine Publishes Results From Pivotal Phase 3 LAVENDER Study Evaluating DAYBUE Efficacy And Safety In Patients With Rett Syndrome
Portfolio Pulse from Happy Mohamed
Acadia Pharmaceuticals announced that Nature Medicine published results from the Phase 3 LAVENDER trial, which evaluated the efficacy and safety of DAYBUE in patients with Rett syndrome. The study demonstrated statistically significant improvement compared to placebo, providing the basis for the first FDA-approved treatment for Rett syndrome.
June 08, 2023 | 3:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Acadia Pharmaceuticals' DAYBUE demonstrated statistically significant improvement in treating Rett syndrome in the Phase 3 LAVENDER trial, leading to FDA approval.
The positive results from the Phase 3 LAVENDER trial, published in Nature Medicine, demonstrate the efficacy and safety of DAYBUE in treating Rett syndrome. This led to the FDA approval of DAYBUE, making it the first approved treatment for Rett syndrome. This is a significant milestone for Acadia Pharmaceuticals and is likely to have a positive impact on the company's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100